단백질 엔지니어링 시장 예측(-2032년) : 제품, 유형, 기술, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Protein Engineering Market is accounted for $3.5 billion in 2025 and is expected to reach $8.6 billion by 2032 growing at a CAGR of 16.2% during the forecast period. Protein engineering is the design and modification of proteins to enhance or create specific functions. Using techniques like directed evolution and rational design, scientists alter protein structures to improve stability, activity, or specificity. Applications include developing enzymes for industrial processes, antibodies for therapeutics, and proteins for diagnostics. It combines molecular biology, computational modeling, and biochemistry to tailor proteins for targeted biological or industrial purposes.

Market Dynamics:

Driver:

Increased use in industrial enzymes

The growing demand for efficient industrial enzymes in biotechnology and pharmaceuticals drives the protein engineering market. These enzymes enhance processes like drug manufacturing and biofuel production. The need for sustainable and cost-effective industrial solutions fuels market growth. Advances in genetic engineering techniques enable the design of high-performance enzymes. The rise in bioprocessing applications supports market expansion. Fueled by industrial needs, protein engineering is experiencing significant growth.

Restraint:

High R&D costs

Protein engineering requires substantial investment in research, including advanced computational tools and laboratory equipment. The complexity of designing novel proteins increases development costs. Small biotech firms often face financial constraints in pursuing innovative projects. The lengthy process of protein optimization adds to the expense. High costs can delay market entry for new solutions. Triggered by financial barriers, R&D costs challenge market growth.

Opportunity:

Development of novel biologics

The development of novel biologics, such as monoclonal antibodies and gene therapies, presents significant opportunities for protein engineering. These biologics address unmet medical needs in areas like cancer and rare diseases. Advances in protein design techniques enhance the efficacy and specificity of biologics. Growing investments in personalized medicine drive demand for engineered proteins. The potential for breakthrough therapies fuels market optimism. Spurred by medical innovations, novel biologics offer substantial growth prospects.

Threat:

Intellectual property disputes

Intellectual property disputes over protein engineering technologies can hinder market growth. Patent conflicts among biotech firms may delay product development and commercialization. The complexity of patent landscapes in protein engineering creates legal uncertainties. High litigation costs can strain resources for smaller companies. Disputes over proprietary techniques disrupt market stability. Influenced by legal challenges, IP disputes threaten sustained market progress.

Covid-19 Impact:

The COVID-19 pandemic accelerated demand for protein engineering in vaccine and therapeutic development. However, disruptions in research activities and supply chains delayed non-COVID projects. The focus on rapid vaccine development highlighted the importance of engineered proteins. Budget reallocations limited funding for other protein engineering initiatives during the crisis. The post-pandemic recovery has spurred investments in biologics and industrial enzymes. Guided by healthcare priorities, the market is rebounding with renewed focus.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is expected to account for the largest market share during the forecast period, due to the critical role of advanced tools in protein design and analysis. High-throughput screening systems and computational platforms drive demand for specialized instruments. The growing complexity of protein engineering projects fuels their adoption. These instruments enable precise protein modification for industrial and medical applications. Rising investments in biotech R&D further support market growth. Powered by technological advancements, the instruments segment holds the largest market share.

The monoclonal antibodies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the monoclonal antibodies segment is predicted to witness the highest growth rate, due to their critical role in targeted therapies for cancer and autoimmune diseases. Advances in protein engineering enhance their specificity and therapeutic efficacy. The rising prevalence of chronic diseases drives demand for monoclonal antibodies. Ongoing research into next-generation biologics fuels market expansion. The focus on personalized medicine accelerates its adoption. Propelled by medical breakthroughs, this segment is set for the highest growth rate.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to its growing biotechnology and pharmaceutical industries. Countries like China and India are investing heavily in bioprocessing and biologics development. The region's focus on affordable healthcare solutions drives demand for engineered proteins. Government support for biotech innovation bolsters market growth. Rapid industrialization further strengthens the market's position. Backed by robust biotech growth, Asia Pacific leads the global market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to its advanced research infrastructure and biotech innovation. The region's focus on personalized medicine and novel biologics fuels demand. Significant investments in R&D by major pharmaceutical companies drive market expansion. The presence of leading biotech firms enhances market growth. Regulatory support for innovative therapies strengthens the region's position. Motivated by cutting-edge research, North America is poised for rapid market growth.

Key players in the market

Some of the key players in Protein Engineering Market include Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Bruker Corporation, Waters Corporation, PerkinElmer, Inc., Amgen Inc., Eli Lilly and Company, Genentech, Inc., Codexis, Inc., Genscript Biotech Corporation, Integrated DNA Technologies, Inc., Novo Nordisk A/S, Sanofi S.A., Johnson & Johnson, Vertex Pharmaceuticals Incorporated, Lonza Group, and Kyowa Kirin Co., Ltd.

Key Developments:

In March 2025, Merck KGaA opened a biologics innovation hub in Asia Pacific, focusing on protein engineering for novel therapeutics. The facility leverages AI and high-throughput screening to develop targeted biologics, addressing unmet medical needs.

In February 2025, Agilent Technologies launched a next-generation protein analysis system for biologics research. Equipped with advanced spectrometry, it supports precise protein modification for industrial and medical applications, enhancing research efficiency and scalability.

Products Covered:

• Instruments
• Consumables
• Software & Services

Types Covered:

• Monoclonal Antibodies
• Erythropoietin
• Interferons
• Vaccines
• Colony-stimulating Factors
• Growth Hormones
• Coagulation Factors
• Other Types

Technologies Covered:

• Rational Protein Design
• Irrational Protein Design

Applications Covered:

• Drug Discovery & Development
• Therapeutic Applications
• Industrial Enzyme Development
• Diagnostics
• Other Applications

End Users Covered:

• Biopharmaceutical Companies
• Contract Research Organizations
• Academic Research Institutes

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Protein Engineering Market, By Product

• 5.1 Introduction
• 5.2 Instruments
• 5.3 Consumables
• 5.4 Software & Services

6 Global Protein Engineering Market, By Type

• 6.1 Introduction
• 6.2 Monoclonal Antibodies
• 6.3 Erythropoietin
• 6.4 Interferons
• 6.5 Vaccines
• 6.6 Colony-stimulating Factors
• 6.7 Growth Hormones
• 6.8 Coagulation Factors
• 6.9 Other Types

7 Global Protein Engineering Market, By Technology

• 7.1 Introduction
• 7.2 Rational Protein Design
• 7.3 Irrational Protein Design

8 Global Protein Engineering Market, By Application

• 8.1 Introduction
• 8.2 Drug Discovery & Development
• 8.3 Therapeutic Applications
• 8.4 Industrial Enzyme Development
• 8.5 Diagnostics
• 8.6 Other Applications

9 Global Protein Engineering Market, By End User

• 9.1 Introduction
• 9.2 Biopharmaceutical Companies
• 9.3 Contract Research Organizations
• 9.4 Academic Research Institutes

10 Global Protein Engineering Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Thermo Fisher Scientific Inc.
• 12.2 Danaher Corporation
• 12.3 Agilent Technologies, Inc.
• 12.4 Bio-Rad Laboratories, Inc.
• 12.5 Merck KGaA
• 12.6 Bruker Corporation
• 12.7 Waters Corporation
• 12.8 PerkinElmer, Inc.
• 12.9 Amgen Inc.
• 12.10 Eli Lilly and Company
• 12.11 Genentech, Inc.
• 12.12 Codexis, Inc.
• 12.13 Genscript Biotech Corporation
• 12.14 Integrated DNA Technologies, Inc.
• 12.15 Novo Nordisk A/S
• 12.16 Sanofi S.A.
• 12.17 Johnson & Johnson
• 12.18 Vertex Pharmaceuticals Incorporated
• 12.19 Lonza Group
• 12.20 Kyowa Kirin Co., Ltd.